Cost analysis of diabetes treatment with glargine insulin or NPH insulin in Spain

被引：0
|
作者：
Rubio-Terrés, C
Rodriguez, J
Bolinder, B
机构：
[1] Aventis Pharma SA, Madrid, Spain
[2] Aventis Pharmaceut, Bridgewater, NJ USA
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64190-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：336 / 336
页数：1
相关论文
共 50 条
  • [41] ADDING INSULIN GLARGINE TO ORAL THERAPY IN PATIENTS WITH TYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN
    Pfohl, M.
    Dippel, F. W.
    Kostev, K.
    Kotowa, W.
    VALUE IN HEALTH, 2008, 11 (06) : A509 - A510
  • [42] Safety and efficacy of insulin glargine compared with NPH insulin in older adults with type 2 diabetes mellitus
    Lee, P. G.
    Chang, A. M.
    Blaum, C.
    Vlajnic, A.
    Miller, M. F.
    Halter, J. B.
    DIABETOLOGIA, 2009, 52 : S382 - S382
  • [43] Insulin glargine is associated with less hypoglycaemia than NPH insulin in older patients with Type 2 diabetes
    Riddle, M
    Massi-Benedetti, M
    Häring, HU
    Dailey, G
    Murray, F
    Lin, Z
    Rosenstock, J
    DIABETOLOGIA, 2004, 47 : A328 - A328
  • [44] Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus
    Schober, E
    Schoenle, E
    Van Dyk, J
    Wernicke-Panten, K
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2002, 15 (04): : 369 - 376
  • [45] A randomized, multicentre trial of insulin glargine versus NPH insulin in people with Type 1 diabetes.
    Home, P
    DIABETOLOGIA, 2002, 45 : A258 - A258
  • [46] Risk of microvascular events following initiation of insulin glargine or NPH insulin in type 2 diabetes in the US
    Kennedy, L.
    Vinik, A.
    Chaudhuri, A.
    Rhoads, G.
    Vaur, L.
    Fonseca, V. A.
    DIABETOLOGIA, 2009, 52 : S453 - S453
  • [47] Safety and Efficacy of Insulin Glargine Compared with NPH Insulin in Older Adults with Type 2 Diabetes: Results from a Pooled Analysis
    Lee, Pearl G.
    Chang, Annette M.
    Blaum, Caroline S.
    Vlajnic, Aleksandra A.
    Miller, Michael F.
    Halter, Jeffrey B.
    DIABETES, 2009, 58 : A155 - A155
  • [48] COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN SPAIN
    Ramirez de Arellano, A.
    Lizan, L.
    Prades, M.
    Morales, C.
    De Luis, D.
    VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
  • [49] Diabetic retinopathy in patients with type 1 diabetes treated with insulin glargine or NPH
    Peters, K
    Garg, SK
    JAckson, WE
    Mackenzie, T
    Queen, J
    Anil, S
    Chase, HP
    DIABETES, 2001, 50 : A443 - A443
  • [50] Insulin glargine versus NPH insulin in critically ill medical patients
    Krumenacker, Laura
    Winters, Shauna
    Faircloth, Barbara
    McMillen, James
    Wylie, Doug
    Barlow, Patrick
    Ranganath, Harsha
    Branca, Paul
    CRITICAL CARE MEDICINE, 2013, 41 (12)
12345